维基百科 中的醫學内容
仅供参考 ，並
不能 視作專業意見。如需獲取醫療幫助或意見，请咨询专业人士。詳見
醫學聲明 。
第八凝血因子製劑 （factor VIII preparation[ 12] [ 13] A型血友病 出血 情況。[ 14] [ 15] 類血友病 （也稱溫韋伯氏疾病）的個體。[ 15]
此藥物經由緩慢靜脈注射 方式給藥。[ 14]
使用此藥物的副作用有皮膚潮紅、呼吸短促、發燒 及溶血反應 。[ 15] 過敏反應 （包括過敏性休克 ）。此種純化的第八凝血因子濃縮物由人類血漿 製成（屬於一種生物製藥 ），[ 15] 基因工程 製造的重組製劑於市面販售（也是一種生物製藥）。有人可能會產生針對此凝血因子的抗體 ，而導致其療效降低。[ 16]
第八凝血因子首次於1940年代被發現，並於1960年代獲得批准用作醫療用途。[ 17] [ 18] 美國食品藥物管理局 （FDA）核准用作醫療用途。[ 19] [ 20] 世界衛生組織基本藥物標準清單 之中。[ 21]
目前尚不清楚個體於懷孕 期間使用是否對胎兒安全。[ 16]
目前尚無足夠的研究數據來評估個體於母乳哺育 期間使用此藥物是否對嬰兒有風險。在服用前，請先諮詢醫師，權衡潛在益處和風險後作決定。[ 22] [ 23]
第八凝血因子不應用於對其或其中任何成分會過敏的個體。治療期間應監測血漿中此因子的水平。[ 24] [ 25]
由人類血漿萃取的第八凝血因子與其他藥物之間並無嚴重、中度或輕度的交互作用。[ 26]
此藥物為粉末形式，先經溶劑溶解後再進行靜脈注射。[ 27] [ 28] 醫療衛生提供者 給藥，或是經前者指導後在家自行給藥。[ 28]
過往治療A型血友病患者的標準方式是將由人血漿中萃取而得的第八凝血因子透過靜脈注射來達成。然而此方法存在個體會因而感染愛滋病 和肝炎 等病毒 的風險。[ 29] [ 29]
用於治療類血友病的第八凝血因子（von Willebrand Factor/Coagulation Factor VIII Complex (Human) ，商品名稱：Wilate）已於2009年在美國獲准用於醫療用途。[ 10] [ 30] [ 31]
第八凝血因子和類似凝血因子的成本被認為"非常昂貴"，[ 27] [ 32] 基因治療 反可能會較為便宜，特別是對那些患有嚴重血友病的個體而言。[ 32]
^ Coagulation Factor VIII, Human . www.drugs.com. [2017-01-08 ] . （原始内容存档 于2017-01-09）. ^ Prescription medicines: registration of new chemical entities in Australia, 2017 . Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-09 ] . ^ Prescription medicines: registration of new chemical entities in Australia, 2016 . Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10 ] . ^ Prescription medicines: registration of new chemical entities in Australia, 2014 . Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10 ] . ^ Prescription medicines and biologicals: TGA annual summary 2017 . Therapeutic Goods Administration (TGA). 2022-06-21 [2024-03-31 ] . ^ Regulatory Decision Summary for Alphanate . 2014-10-23. ^ Health Canada New Drug Authorizations: 2016 Highlights . Health Canada . 2017-03-14 [2024-04-07 ] . ^ Adynovi EPAR . European Medicines Agency. 2018-01-08 [2024-06-20 ] . ^ Advate EPAR . European Medicines Agency. 2004-03-02 [2024-06-20 ] . ^ 10.0 10.1 von Willebrand Factor/Coagulation Factor VIII Complex (Human) (von willebrand factor/coagulation factor viii complex- human powder, for solution . DailyMed. 20 November 2019 [13 November 2024] . ^ von Willebrand Factor/Coagulation Factor VIII Complex (Human) (von willebrand factor/coagulation factor viii complex- human powder, for solution . DailyMed. 2010-08-20 [2024-11-13 ] . ^ Christopher D. Hillyer; Leslie E. Silberstein, Paul M. Ness, Kenneth C. Anderson, John D. Roback. Blood Banking and Transfusion Medicine: Basic Principles and Practice 2. Elsevier Health Sciences. 2006: 353. ISBN 9780443069819 ^ Foster PA, Zimmerman TS. Factor VIII structure and function. Blood Rev. 1989 Sep;3(3):180-91. doi: 10.1016/0268-960x(89)90015-5. PMID: 2506958.
^ 14.0 14.1 World Health Organization . Stuart MC, Kouimtzi M, Hill SR , 编. WHO Model Formulary 2008. World Health Organization. 2009: 259–60. ISBN 9789241547659hdl:10665/44053 ^ 15.0 15.1 15.2 15.3 British National Formulary : BNF 69. British Medical Association. 2015: 171. ISBN 978-0857111562 ^ 16.0 16.1 Alphanate – Summary of Product Characteristics (SPC) – (eMC) . www.medicines.org.uk. [2017-01-08 ] . （原始内容存档 于2017-01-09）. ^ Potts DM. Chapter 5 . Queen Victoria's Gene: Haemophilia and the Royal Family. The History Press. 2011. ISBN 978-0752471969存档 于2017-01-09）. ^ High KA. In vivo characteristics of rDNA Factor VIII: The impact for the future in hemophilia care . Sibinga CS, Das PC, Overby LR (编). Biotechnology in blood transfusion: Proceedings of the Twelfth Annual Symposium on Blood Transfusion, Groningen 1987, organized by the Red Cross Blood Bank Groningen-Drenthe. Springer Science & Business Media. 2012: 224. ISBN 978-1461317616doi:10.1007/978-1-4613-1761-6_19 存档 于2017-01-09）. ^ Brownlee GG, Giangrande PL. Clotting factors VIII and IX . Buckel P (编). Recombinant Protein Drugs. Birkhäuser. 2012: 79. ISBN 978-3034883467存档 于2017-01-09）. ^ Zimring JC, Duncan A. Chapter 25 - Coagulation Factor Preparations . Hillyer CD (编). Blood Banking and Transfusion Medicine: Basic Principles & Practice. Elsevier Health Sciences. 2006: 353. ISBN 0443069816doi:10.1016/B978-0-443-06981-9.50030-2 存档 于2017-01-09）. ^ World Health Organization . World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 ^ Antihemophilic factor viii and von willebrand factor (intravenous route) . Mayo Clinic. [2024-12-05 ] . ^ Antihemophilic Factor . Drugs and Lactation Database (LactMed®) [Internet]. [2024-12-05 ] . ^ Anti-Haemophilia Factor . Pediatric Oncall. [2024-12-05 ] . ^ Antihemophilic Factor (Factor Viii), Human - Injection . HealthLinkBC. [2024-12-05 ] . ^ factor VIII . MedicineNet. [2024-12-05 ] . ^ 27.0 27.1 Nathwani AC, Davidoff AM, Tuddenham EG. Gene Therapy for Hemophilia. Hematology/Oncology Clinics of North America. October 2017, 31 (5): 853–868. PMID 28895852 S2CID 3779939 doi:10.1016/j.hoc.2017.06.011 ^ 28.0 28.1 Antihemophilic factor viii and von willebrand factor (intravenous route) . Mayo Clinic. [2024-12-04 ] . ^ 29.0 29.1 Powell, Jerry S. Recombinant factor VIII in the management of hemophilia A: current use and future promise . Therapeutics and Clinical Risk Management. 2009-05-20, 5 : 391–402 [2024-12-04 ] . doi:10.2147/tcrm.s4412 ^ Wilate . U.S. Food and Drug Administration. 13 November 2024 [13 November 2024] . ^ HIGHLIGHTS OF PRESCRIBING INFORMATION for Wilate . FDA. [2024-12-04 ] . ^ 32.0 32.1 Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis . Blood Advances. July 2018, 2 (14): 1792–1798. PMC 6058236 PMID 30042145 doi:10.1182/bloodadvances.2018021345
